Searchable abstracts of presentations at key conferences in endocrinology

ea0022p578 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Use of the desmopressin test in the differential diagnosis of Pseudo-Cushing state from Cushing's disease

Tirabassi Giacomo , Faloia Emanuela , Papa Roberta , Furlani Giorgio , Boscaro Marco , Arnaldi Giorgio

Context: The desmopressin (DDAVP) test has been proposed to discriminate CushingÂ’s disease (CD) from Pseudo-Cushing states (PC); however, current information on its value is scarce and contradictory.Objective: To assess the ability of the DDAVP test in distinguishing between these conditions, with emphasis on subjects with mild hypercortisolism.Design: Retrospective/prospective study.Setting: Division of...

ea0020p580 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Human corticotropin releasing hormone (hCRH) test performance in the differential diagnosis between Cushing's disease and pseudo-Cushing state is enhanced by combined ACTH and cortisol analysis

Tirabassi Giacomo , Arnaldi Giorgio , Papa Roberta , Furlani Giorgio , Trementino Laura , Cardinaletti Marina , Faloia Emanuela , Boscaro Marco

Objective: The corticotropin releasing hormone (CRH) test does not reliably distinguish between CushingÂ’s disease (CD) and normality or pseudo-Cushing state (PC). In this study we assessed whether the application of novel criteria could enhance its diagnostic performance.Design: Retrospective study.Patients: Fifty-one subjects with CD, 26 with PC and 31 control subjects (CT).Measurements: All subjects un...

ea0035p957 | Steroid metabolism and action | ECE2014

Role of clinical risk factors and polymorphisms in glucocorticoid receptor gene in the determining the risk of developing new-onset diabetes after kidney transplantation

Michetti Grazia , Trementino Laura , Marcelli Giorgia , Apolloni Gloria , Taruscia Domenica , Frasca Giovanni Maria , Boscaro Marco , Faloia Emanuela , Arnaldi Giorgio

Introduction: New onset diabetes after transplantation (NODAT) is a recognized metabolic complication of kidney transplantation: its rates at 12 months after transplantation is between 20 and 50% for kidney recipients and it is associated with increased risks of graft rejection, infection, cardiovascular disease and death. Transplant-specific risk factors for NODAT,such as corticosteroids and calcineurin inhibitors, play a dominant role in its pathogenesis. Furthermore polymor...